OrbiMed
TEVA icon

OrbiMed’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

OrbiMed’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,935,200
Closed -$18.7M – 179
2020
Q4 		$18.7M Hold
1,935,200
– – 0.16% 104
2020
Q3 		$17.4M Hold
1,935,200
– – 0.22% 91
2020
Q2 		$23.9M Buy
+1,935,200
New +$21.9M 0.34% 70
2019
Q2 		– Sell
-4,079,000
Closed -$64M – 135
2019
Q1 		$64M Buy
+4,079,000
New +$71.9M 0.99% 32
2017
Q4 		– Sell
-405,500
Closed -$7.14M – 143
2017
Q3 		$7.14M Sell
405,500
-120,800
-23% -$2.72M 0.07% 115
2017
Q2 		$17.5M Buy
526,300
+113,700
+28% +$3.52M 0.18% 84
2017
Q1 		$13.2M Sell
412,600
-201,900
-33% -$6.89M 0.15% 87
2016
Q4 		$22.3M Sell
614,500
-1,216,900
-66% -$48.6M 0.28% 66
2016
Q3 		$84.3M Sell
1,831,400
-928,400
-34% -$48.4M 0.96% 40
2016
Q2 		$139M Buy
2,759,800
+63,800
+2% +$3.4M 1.45% 22
2016
Q1 		$144M Buy
2,696,000
+250,000
+10% +$14.7M 1.52% 21
2015
Q4 		$161M Buy
2,446,000
+247,000
+11% +$15.3M 1.45% 23
2015
Q3 		$124M Buy
2,199,000
+1,892,000
+616% +$123M 1.25% 25
2015
Q2 		$18.1M Sell
307,000
-784,000
-72% -$48.4M 0.15% 87
2015
Q1 		$68M Buy
1,091,000
+691,000
+173% +$40.2M 0.58% 48
2014
Q4 		$23M Sell
400,000
-262,000
-40% -$14.6M 0.22% 71
2014
Q3 		$35.6M Buy
+662,000
New +$35.1M 0.37% 53

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Abrams Capital Management
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Migdal Insurance & Financial Holdings
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Menora Mivtachim Holdings
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Clal Insurance
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

OrbiMed's TEVA Position: Q1 2021 in Review

OrbiMed sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2021, closing a stake of 1,935,200 shares — an estimated $18.7M sold.

OrbiMed first reported a position in TEVA in Q3 2014 and held it in 17 quarters. The position peaked at $161M in Q4 2015. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

  • OrbiMed reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2021 after selling out during the quarter.
  • OrbiMed sold 1,935,200 Teva Pharmaceutical Industries Limited shares in Q1 2021, an estimated $18.7M.
  • OrbiMed first reported a position in Teva Pharmaceutical Industries Limited in Q3 2014 and held it in 17 quarters.
  • OrbiMed's Teva Pharmaceutical Industries Limited position peaked at $161M in Q4 2015.
  • 451 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.